Back to Report Store Home

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

  • Published: May-2018
  • Report Code: GBIHC474MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Breast Cancer Therapeutics, APAC, Age-Standardized Incidence (per 100,000 population), 2012 16

Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2012, 2013 and 2014 17

Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I–III 26

Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 27

Figure 5: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Positive Breast Cancer Patients, 2018 54

Figure 6: Breast Cancer Therapeutics Market, Global, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of HER2-Negative Breast Cancer Patients, 2018 56

Figure 7: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products, 2018 63

Figure 8: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 65

Figure 9: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 66

Figure 10: Breast Cancer Therapeutics Market, APAC, Neratinib, Market Forecast ($m), 2020–2024 69

Figure 11: Breast Cancer Therapeutics Market, APAC, Abemaciclib, Market Forecast ($m), 2018–2024 71

Figure 12: Breast Cancer Therapeutics Market, APAC, Olaparib, Market Forecast ($m), 2018–2024 73

Figure 13: Breast Cancer Therapeutics Market, APAC, Talazoparib, Market Forecast ($m), 2020–2024 75

Figure 14: Breast Cancer Therapeutics Market, APAC, Pembrolizumab, Market Forecast ($m), 2020–2024 77

Figure 15: Breast Cancer Therapeutics Market, APAC, Atezolizumab Forecast ($m), 2021–2024 79

Figure 16: Breast Cancer Therapeutics Market, APAC, Taselisib, Market Forecast ($m), 2020–2024 81

Figure 17: Breast Cancer Therapeutics Market, APAC, Alpelisib, Market Forecast ($m), 2021–2024 83

Figure 18: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Positive Breast Cancer, 2018 89

Figure 19: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for HER2-Negative Breast Cancer, 2018 90

Figure 20: Breast Cancer Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for TNBC, 2018 91

Figure 21: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Positive Breast Cancer Marketed and Pipeline Products, 2018 92

Figure 22: Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Negative Breast Cancer Marketed and Pipeline Products, 2018 93

Figure 23: Breast Cancer Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007–2017 95

Figure 24: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007–2017 96

Figure 25: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007–2017 97

Figure 26: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007–2017 98

Figure 27: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007–2017 99

Figure 28: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007–2017 100

Figure 29: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2007–2017 101

Figure 30: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2007–2017 102

Figure 31: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2007–2017 103

Figure 32: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 104

Figure 33: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 105

Figure 34: Breast Cancer Therapeutics Market, APAC, Treatment Patterns (‘000), 2017–2024 108

Figure 35: Breast Cancer Therapeutics Market, APAC, Market Size ($bn), 2017–2024 110

Figure 36: Breast Cancer Therapeutics Market, India, Treatment Patterns (‘000), 2017–2024 111

Figure 37: Breast Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2017–2024 112

Figure 38: Breast Cancer Therapeutics Market, India, Market Size ($m), 2017–2024 113

Figure 39: Breast Cancer Therapeutics Market, China, Treatment Patterns (‘000), 2017–2024 115

Figure 40: Breast Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2017–2024 116

Figure 41: Breast Cancer Therapeutics Market, China, Market Size ($m), 2017–2024 118

Figure 42: Breast Cancer Therapeutics Market, Australia, Treatment Patterns (‘000), 2017–2024 119

Figure 43: Breast Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017–2024 120

Figure 44: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2017–2024 121

Figure 45: Breast Cancer Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017–2024 122

Figure 46: Breast Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017–2024 123

Figure 47: Breast Cancer Therapeutics Market, South Korea, Market Size ($m), 2017–2024 125

Figure 48: Breast Cancer Therapeutics Market, Japan, Treatment Patterns (‘000), 2017–2024 126

Figure 49: Breast Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017–2024 127

Figure 50: Breast Cancer Therapeutics Market, Japan, Market Size ($bn), 2017–2024 129

Figure 51: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2007–2017 135

Figure 52: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 136

Figure 53: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2017 137

Figure 54: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007–2017 138

Figure 55: Breast Cancer Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007–2017 139

Figure 56: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2007–2017 142

Figure 57: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 143

Figure 58: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2007–2017 144

Figure 59: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2007–2017 145

Figure 60: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007–2017 146

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards